VANCOUVER, CANADA – December 30, 2014 – Evasc today announced that the eCLIPs Bifurcation Remodeling System has been granted CE Mark approval for commercialization within the European Union and any country that accepts CE mark approval.
eCLIPs is a new class of endovascular device designed for treating intracranial aneurysms. Intracranial aneurysms cause almost 500,000 deaths worldwide each year, and half the victims are younger than 50. Over 120,000 patients are treated endovascularly per year.
“After 7 years of development, we are excited to be able to make eCLIPs available to a broader group of patients,” said Dr. Donald Ricci, President and Chief Executive Officer of Evasc. “Wide-neck bifurcation aneurysms have historically been very difficult to treat. eCLIPs represents a breakthrough step forward in the treatment of these aneurysms.”
In development since 2008, eCLIPs is a patented endovascular device designed to treat 95% of cerebral aneurysm cases and is currently targeted for use in challenging wide-neck bifurcations. eCLIPs combines the best properties of stents and diverters and can be used for coil retention and to enhance flow disruption. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while protecting and providing a platform for endothelial growth across the bifurcation neck. To date, eCLIPs has been used to treat cerebral aneurysms in 10 patients.
Evasc is a privately-held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc is headquartered in Vancouver, Canada.
Evasc is on the web at www.evasc.com.
For more information, contact Scott Wilson at +1 (604) 742-3811, email@example.com.